Headache and Migraine

Zosano Pharma noted that the DRL does not reflect the final FDA decision on the application, though the approval of zolmitriptan by its PDUFA action date of October 20, 2020, is no longer likely as a result.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 25, 2020.

The current perspective on the care of patients and the anticipated developments of the future are detailed in part 3 of this special 3-part multimedia series on the evolution of migraine care.

The neurology resident at NYU Langone shared her thoughts on the need for publication of clinician-based data and why maintaining a high level of mental health remains a top priority during the COVID-19 pandemic.

The ongoing fight to add to the epidemiologic understanding of migraine is explored in part 2 of this special 3-part multimedia series on the evolution of migraine care.

In part 2 of this interview, Leah Croll, MD, a neurology resident on the front lines of the COVID-19 pandemic, describes how her resident program experience was impacted by the pandemic.

Mind Moments, a podcast from NeurologyLive, brings you an exclusive interview with Stewart Tepper, MD, in part 1 of this special 3-part multimedia series on the evolution of migraine care.

Leah Croll, MD, a neurology resident on the front lines of the COVID-19 pandemic, shares details from her study on the psychosocial impact on physicians and her first-hand experience.

The neurology resident at NYU Langone described psychosocial implications that physicians faced during the COVID-19 pandemic and the toll it takes on them.

Findings suggest that compared with isolated cases, both earlier age at initial episode and a higher prevalence of personal and family history of migraine are linked to TGA recurrence.

Neurology News Network for the week ending August 29, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 28, 2020.

The data support and extend the safe use of combination treatment with rimegepant and CGRP monoclonal antibodies in migraine that was initially reported in 2 earlier cases.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 21, 2020.

A follow-up cohort study demonstrates that educating optometrists on the importance and utility of a validated migraine screening tool is a simple, low-time investment intervention, the researchers stated.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 14, 2020.

A review of clinical literature and evidence suggests that the gammaCore device (electroCore) is safe and effective in the treatment of cluster headache and migraine, and carries potential to treat more.

Trial data suggest that management of vitamin D deficiency should be considered in patients with frequent attacks of benign paroxysmal positional vertigo.

Neurology News Network for the week ending August 8, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 7, 2020.

Kathleen Digre, MD, past president of the American Headache Society, discusses the barriers to correct identification and treatment of eye symptoms in people with migraine.

An overview of the tweet chat on mental health in neurological disorders, featuring highlighted contributions from the medical community.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 31, 2020.

The gepant agent significantly reduced mean monthly migraine days across all 3 doses—10 mg, 30 mg, and 60 mg—compared with placebo over the 12-week treatment period.

Join NeurologyLive and the Women Neurologist Group on Twitter to discuss the importance of mental health and wellness in neurologic disorders.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 24, 2020.

The director of the Neurology Residency Program at Weill Cornell Medicine highlighted some of the differences in types of headaches that patients with COVID-19 experience, as well as overall takeaways from the pandemic itself.

REN may offer a novel alternative for current pharmacological and non-pharmacological treatments in chronic migraine that combines efficient treatment with minimal adverse effects.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 17, 2020.

The internal medicine resident physician at Montefiore Health System provided an overview of the study he and colleagues conducted on patients using onabotulinumtoxinA and CGRP agents in tandem.